Clifford Swan Investment Counsel LLC Sells 832 Shares of Edwards Lifesciences Co. (NYSE:EW)

Clifford Swan Investment Counsel LLC lessened its holdings in Edwards Lifesciences Co. (NYSE:EW) by 0.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 253,593 shares of the medical research company’s stock after selling 832 shares during the quarter. Clifford Swan Investment Counsel LLC’s holdings in Edwards Lifesciences were worth $18,773,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. SteelPeak Wealth LLC grew its stake in shares of Edwards Lifesciences by 24.9% during the 3rd quarter. SteelPeak Wealth LLC now owns 3,666 shares of the medical research company’s stock worth $242,000 after acquiring an additional 732 shares during the period. JFS Wealth Advisors LLC grew its stake in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after acquiring an additional 166 shares during the period. HM Payson & Co. grew its stake in shares of Edwards Lifesciences by 18.5% during the 3rd quarter. HM Payson & Co. now owns 7,233 shares of the medical research company’s stock worth $477,000 after acquiring an additional 1,128 shares during the period. Chicago Partners Investment Group LLC grew its stake in shares of Edwards Lifesciences by 8.3% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 7,055 shares of the medical research company’s stock worth $498,000 after acquiring an additional 542 shares during the period. Finally, Invesco LLC grew its stake in shares of Edwards Lifesciences by 14.1% during the 3rd quarter. Invesco LLC now owns 3,469 shares of the medical research company’s stock worth $229,000 after acquiring an additional 430 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $71.61 on Friday. The stock has a market cap of $42.24 billion, a P/E ratio of 10.27, a PEG ratio of 4.82 and a beta of 1.10. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The business’s 50-day moving average price is $72.64 and its two-hundred day moving average price is $70.27.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Friday, February 28th. The stock was sold at an average price of $70.78, for a total value of $796,275.00. Following the completion of the sale, the chief financial officer now directly owns 30,387 shares of the company’s stock, valued at $2,150,791.86. The trade was a 27.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 37,739 shares of company stock worth $2,799,104 over the last quarter. 1.29% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Evercore ISI cut their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research note on Wednesday, February 12th. Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. The Goldman Sachs Group increased their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Finally, Morgan Stanley increased their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.